The brokerage expects domestic-focused pharma companies to outperform peers exposed to high-value US generic opportunities, with Sun Pharma, Cipla and Jubilant Pharmova emerging as its preferred picks ahead of Q1 FY27 results.
The brokerage expects domestic-focused pharma companies to outperform peers exposed to high-value US generic opportunities, with Sun Pharma, Cipla and Jubilant Pharmova emerging as its preferred picks ahead of Q1 FY27 results.
<iframe src="https://hindustansphere.com/embed/cluster/c912cb1fc6c6cde2a85415d6d682a006996b5291" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sun Pharma, Cipla Among Systematix's Top Pharma Picks Ahead Of Q1 Results — Full List Inside"></iframe>
